Prostate Cancer: Fighting the FDA for Your Life

Eduardo Garcia:

Yes, that's correct. I'm in San Diego.

Andrew Schorr:

And you're 84 years old. And I imagine you have more advanced prostate cancer, and you were in a clinical trial for this drug, Provenge, correct?

Eduardo Garcia:

Yes, I was very lucky to have that chance to do that.

Andrew Schorr:

Well, that's what I was going to ask. Did it help you as far as controlling the prostate cancer?

Eduardo Garcia:

It not only helped me control the prostate cancer, it helped me live six years.

Andrew Schorr:

Wow.

Eduardo Garcia:

And I'm talking about living normally, you know, with the quality of life, as you call it. Before I had the treatment, I was feeling terrible. You know, I was tired. I didn't want to go out of the house or anything. Now I have a normal life. I travel. In fact, I was in Washington not too long ago talking to the panel that they had with the doctors from the FDA.

Andrew Schorr:

Right.

Eduardo Garcia:

And so, you know, I have a normal life. Thank god for that.

Andrew Schorr:

So, Eduardo, when the FDA makes the decision to ask for more data and delay approval, even though the hearings were very positive for the manufacturer, Dendreon, which coincidently is here in Seattle where I am, you must have just been baffled.

Eduardo Garcia:

Definitely. It was because I thought that when those doctors, you know, they okayed that part, and so they probably know more about it than the FDA, so I don't understand why are they hesitating to okay it since it's completely harmless? Nobody has been sick taking that treatment. Maybe it's not a miracle drug. It has not saved everybody, but it certainly saved some people, and if they are going to give you even 2 or 3 years out of your life, it's worth it.

Andrew Schorr:

Right. I couldn't agree with you more. Let's meet another gentleman who has been affected by prostate cancer, and I hope I pronounce this right, Ted Girgus. Did I get it right, Ted?

Ted Girgus:

Andrew, that was perfect, thank you.

Advertisement
Join Our Community Register for Events Read Our Latest Blog
Advertisement

Page last updated on May 5, 2016